Doctor of Philosophy (Ph. D) Degree in the relevant field from a recognized University / Institution and first class or equivalent at either Bachelors or Masters level in the relevant branch.
1st class Masters degree in Life Sciences from a recognized University with 2 years experience in the related field or 2nd class Masters Degree with Ph.D in relevant subject from a recognized University.
Postgraduate in Genetics & Plant Breeding/Plant Pathology/Agricultural Botany/Plant Biotechnology/ or any other branch of Life Science with at least 55% marks. Candidates who have qualified National Eligibility Tests ICAR, CSIR, UGC-NET and GATE
Applicants must be nationals of Djibouti, Ethiopia, Kenya or Uganda in order to apply. Displaced researchers currently working in any of the four countries are considered nationals of these countries.
The overall objectives of the BIO-GRID network should be to create a robust ecosystem where bioinformatics serves as the catalyst for transformative discoveries, bridging the gap between data
Evaluate the quality and integrity of study site practices related to the proper conduct of the protocol and adherence to applicable regulations. Escalate quality issues as appropriate.
Works in close collaboration with the external service provider and Investigators to ensure quality and quantity commitments are achieved in a timely and efficient manner.
Managing initial clinical trial application submissions in the EU according to the Clinical Trial Regulation and all changes during the life cycle of clinical trials.
Regulatory Coordinator will support the Director, Regulatory Affairs and other Senior Directors in International Markets to organize and perform required tasks for regulatory affairs in order to maintain compliance with current regulations and in-house standards.
CuraTeQ Biologics Private Limited, a wholly owned subsidiary of Aurobindo Pharma Ltd, has received a Notice of Compliance (NOC) from Health Canada’s Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Dyrupeg™, its pegylated filgrastim biosimilar.
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Everolimus Tablets for Oral Suspension. The approval covers 2 mg, 3 mg and 5 mg strengths.